转染试剂和仪器市场－全球产业规模、份额、趋势、机会及预测（依方法、应用、地区及竞争格局划分，2021-2031年）

全球转染试剂和仪器市场预计将从 2025 年的 13.1 亿美元成长到 2031 年的 23.1 亿美元，复合年增长率为 9.91%。

该行业涵盖用于将外来性核酸导入细胞以进行蛋白质表现和基因分析的化学製剂和物理装置。该市场的成长主要受生物製药研究的快速发展以及越来越多的先进候选疗法进入临床试验的驱动。日益活性化的研究活动直接需要可靠的载体生产递送系统。根据美国基因与细胞治疗学会 (ASGCT) 预测，到 2024 年，全球将有超过 4000 种基因、细胞和 RNA 疗法正在研发中，这凸显了高效转染工具对于支持不断发展的基因医学领域的重要性。

儘管市场呈现积极的成长趋势，但由于许多转染方法存在细胞毒性，因此仍面临严峻的挑战。化学试剂和物理方法常常会导致细胞压力和死亡，从而影响实验的有效性并降低生产产量。研究人员常常难以在高转染效率和细胞活力之间取得平衡，尤其是在工业化应用规模化生产过程中。因此，如何在转染过程中维持细胞健康仍然是限制这些技术更广泛商业性化应用的一大障碍。

市场驱动因素

细胞和基因治疗研究的快速发展是全球转染试剂和设备市场的主要驱动力。随着生物製药开发商从早期药物发现阶段过渡到商业化生产阶段，对用于病毒载体生产和细胞疗法设计的高效转染技术的需求日益增长。这一趋势得到了近期监管审批结果的直接支持。 2025年1月，国际细胞和基因治疗协会（ISCT）报告称，2024年共有7种细胞和基因治疗产品获得美国食品药物管理局（FDA）核准。这些核准需要强大的转染级质体和脂质奈米颗粒供应链，为试剂供应商提供持续的收入来源。为了满足不断增长的商业性需求，各大製药公司正在大幅扩大其产能。例如，根据Clinical Trials Arena报道，葛兰素史克（GSK）将于2024年10月在美国投资8亿美元新建一家原料药和製剂生产工厂，这凸显了对依赖先进转染工作流程的基础设施的大量资金投入。

政府加强对生物医学领域的支持和资助，降低了学术界和工业界实验室的资金门槛，进一步加速了转染技术的应用。公共部门的津贴和生产资金对于科研基础设施的现代化至关重要，使科学家能够购买先进的电穿孔系统和新型化学试剂。英国政府于2024年11月宣布拨款5.2亿英镑设立生命科学创新製造基金，旨在增强国内製造业的韧性，这就是一个典型的例子。这笔资金不仅能补贴下一代转染设备的高成本，还能降低新型非病毒载体的研发风险。因此，政府支持的财政奖励策略有效地扩大了基本客群，使中小型生物技术公司和大学研究中心能够将先进的转染方法整合到其标准工作流程中。

市场挑战

全球转染试剂和仪器市场面临的一大挑战是转染方法固有的细胞毒性，直接影响生产效率和实验成功率。当化学试剂或物理装置穿透细胞膜递送核酸时，它们常常会引起细胞毒性，导致大量细胞死亡和细胞行为改变。这种细胞活力的降低在生物製药生产的规模化阶段尤其不利，因为维持高产量的健康细胞对于基因治疗和病毒载体的商业性可行性至关重要。因此，批次失败带来的经济风险迫使製造商限制生产批次，减缓了这些技术的广泛应用。

根据美国临床肿瘤学会 (ASCO) 2024 年的生产数据显示，某些上市细胞治疗产品的不合格率 (OOS) 高达 28%，其中细胞活力低被认为是主要原因。如此高的不合格率凸显了生产过程中细胞毒性压力造成的重大瓶颈。这种不可靠性导致需要重复生产週期和严格的品管措施，从而推高了销货成本，并对市场扩张构成重大障碍。

市场趋势

随着基因治疗开发商日益寻求符合严格监管标准的原料，临床生产中向GMP级试剂的转变正在重塑市场格局。随着候选疗法从早期研究走向商业化，供应商正积极获得专业知识，以提供符合良好生产规范（GMP）的转染产品。这种产业整合体现在对高品质试剂生产商的高价值策略收购中，以确保供应链的可靠性。据默克集团（Merck KGaA）称，该公司于2024年5月达成最终协议，以约6亿美元收购Mirus Bio，以增强其一体化病毒载体生产能力。这项大规模投资标誌着在确保高性能、合规的转染平台方面迈出了关键一步，而这对于现代基因药物的大规模生产至关重要。

同时，克服病毒载体固有的安全性和生产限制的需求正在加速向非病毒递送系统的转变。脂质奈米颗粒和其他化学转染方法越来越受到青睐，可用于将mRNA和基因编辑装置直接递送至患者体内。这项技术进步促使大量创业投资涌入那些致力于开发下一代体内递送技术的公司，这些技术无需复杂的体外操作。根据BioSpace报道，Capstan Therapeutics于2024年3月完成了超额认购的B轮资金筹措，筹集了1.75亿美元，用于推进其基于靶向非病毒转染的体内CAR-T疗法产品线。这笔资金的注入显示市场对非病毒机製作为未来复杂生物药物给药标准越来越有信心。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球转染试剂和仪器市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过以下方法（电穿孔、脂质体、粒子轰击、显微注射、腺病毒载体、磷酸钙、DEAE-聚葡萄糖、磁珠、活化树状聚合物、雷射感染）
  • 依应用领域（基因表现研究、蛋白质生产、基因改造模型、治疗药物传递、癌症研究、生物医学研究）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美转染试剂与仪器市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲转染试剂和仪器市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区转染试剂和仪器市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东及非洲转染试剂及仪器市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美转染试剂与仪器市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球转染试剂与仪器市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific, Inc.
• Promega Corporation
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories Inc.
• Merck KGaA
• OriGene Technologies Inc.
• MaxCyte, Inc.
• POLYPLUS TRANSFECTION SA
• Horizon Discovery Ltd.
• PromoCell GmbH

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Transfection Reagent and Equipment Market is projected to expand from USD 1.31 Billion in 2025 to USD 2.31 Billion by 2031, reflecting a CAGR of 9.91%. This industry encompasses the chemical formulations and physical instruments used to introduce exogenous nucleic acids into cells for protein expression and gene analysis. The market is chiefly supported by the rapid growth of the biopharmaceutical research sector and the increasing volume of advanced therapeutic candidates entering clinical trials. This surge in research activity creates a direct demand for reliable delivery systems needed for vector manufacturing. According to the American Society of Gene & Cell Therapy, over 4,000 gene, cell, and RNA therapies were in development globally in 2024, highlighting the critical need for efficient transfection tools to support the expanding field of genetic medicine.

Despite this positive growth trajectory, the market faces a significant hurdle regarding the cellular toxicity associated with many transfection methods. Chemical reagents and physical techniques frequently induce cellular stress or death, which compromises experimental validity and reduces production yields in manufacturing. Researchers often struggle to balance high delivery efficiency with cell viability, particularly when scaling operations for industrial applications. Consequently, the technical difficulty of preserving cellular health during the transfection process remains a critical obstacle that complicates the broader commercial expansion of these technologies.

Market Driver

The rapid expansion of cell and gene therapy research acts as the primary catalyst for the global transfection reagent and equipment market. As biopharmaceutical developers transition from early-stage discovery to commercial-scale manufacturing, the requirement for high-efficiency transfection technologies to produce viral vectors and engineer cell-based therapies has intensified. This trend is directly validated by recent regulatory successes; the International Society for Cell & Gene Therapy reported in January 2025 that seven distinct cell and gene therapy products received FDA approval in 2024. Such approvals necessitate robust supply chains for transfection-grade plasmids and lipid nanoparticles, driving recurring revenue for reagent suppliers. To support this escalating commercial demand, major pharmaceutical entities are heavily expanding their production capabilities. For instance, according to Clinical Trials Arena, GSK invested $800 million in October 2024 for new drug substance and product manufacturing facilities in the United States, underscoring the massive capital flow into infrastructure that relies on advanced transfection workflows.

Growth in government initiatives and funding for biomedical sciences further accelerates the adoption of transfection technologies by lowering financial barriers for academic and industrial laboratories. Public sector grants and manufacturing funds are critical for modernizing research infrastructure, allowing scientists to procure advanced electroporation systems and novel chemical reagents. A prime example of this fiscal support occurred when the UK Government announced a £520 million commitment in November 2024 for the Life Sciences Innovative Manufacturing Fund to bolster domestic production resilience. This influx of capital not only subsidizes the high costs associated with next-generation transfection equipment but also de-risks the development of novel non-viral delivery vectors. Consequently, state-sponsored financial stimuli are effectively widening the customer base, enabling smaller biotech firms and university hubs to integrate sophisticated transfection methods into their standard operational workflows.

Market Challenge

The primary challenge hampering the Global Transfection Reagent and Equipment Market is the inherent cellular toxicity associated with transfection methods, which directly undermines manufacturing efficiency and experimental success. When chemical reagents or physical instruments breach cell membranes to introduce nucleic acids, they frequently trigger cytotoxicity, leading to significant cell death or altered cellular behavior. This reduction in cell viability is particularly detrimental during the scale-up phase of biopharmaceutical production, where maintaining high yields of healthy cells is essential for the commercial viability of gene therapies and viral vectors. Consequently, the financial risks associated with batch failures force manufacturers to limit production runs, slowing the broader adoption of these technologies.

According to the American Society of Clinical Oncology (ASCO), manufacturing data from 2024 indicated that out-of-specification (OOS) rates for certain commercial cell therapy products reached as high as 28%, with low cell viability identified as a primary contributing factor. Such high failure rates underscore the critical bottleneck caused by cytotoxic stress during production. This unreliability necessitates repeated manufacturing cycles and extensive quality control measures, inflating the cost of goods sold and creating a substantial obstacle to market expansion.

Market Trends

The transition to GMP-grade reagents for clinical manufacturing is reshaping the market as gene therapy developers increasingly demand raw materials that meet stringent regulatory standards. As therapeutic candidates progress from early research to commercialization, suppliers are aggressively acquiring specialized capabilities to provide transfection formulations compliant with Good Manufacturing Practices. This industry consolidation is evident in high-value strategic acquisitions targeting premium reagent producers to secure supply chain reliability. According to Merck KGaA, the company entered into a definitive agreement in May 2024 to acquire Mirus Bio for approximately $600 million to bolster its integrated viral vector manufacturing offer. This substantial investment underscores the critical pivot toward securing high-performance and regulatory-compliant transfection platforms essential for the scalable production of modern genetic medicines.

A simultaneous shift toward non-viral delivery systems is accelerating due to the need to overcome the safety and manufacturing limitations inherent in viral vectors. Lipid nanoparticles and other chemical transfection methods are increasingly preferred for delivering mRNA and gene-editing machinery directly into patients. This technical evolution is attracting significant venture capital into companies developing next-generation in vivo delivery technologies that bypass complex ex vivo manipulation. According to BioSpace, Capstan Therapeutics raised $175 million in an oversubscribed Series B financing in March 2024 to advance its pipeline of in vivo CAR-T therapies which rely on targeted non-viral transfection. Such capital infusions highlight the growing market confidence in non-viral mechanisms as the future standard for administering complex biologic drugs.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Promega Corporation
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories Inc.
• Merck KGaA
• OriGene Technologies Inc.
• MaxCyte, Inc.
• POLYPLUS TRANSFECTION S.A.
• Horizon Discovery Ltd.
• PromoCell GmbH

Report Scope

In this report, the Global Transfection Reagent and Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transfection Reagent and Equipment Market, By Method

• Electroporation
• Liposomes
• Particle Bombardment
• Microinjection
• Adenoviral Vectors
• Calcium Phosphate
• DEAE-dextran
• Magnetic Beads
• Activated Dendrimers
• Laserfection

Transfection Reagent and Equipment Market, By Application

• Gene Expression Studies
• Protein Production
• Transgenic Models
• Therapeutic Delivery
• Cancer Research
• Biomedical Research

Transfection Reagent and Equipment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Transfection Reagent and Equipment Market.

Available Customizations:

Global Transfection Reagent and Equipment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Transfection Reagent and Equipment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Method (Electroporation, Liposomes, Particle Bombardment, Microinjection, Adenoviral Vectors, Calcium Phosphate, DEAE-dextran, Magnetic Beads, Activated Dendrimers, Laserfection)
  • 5.2.2. By Application (Gene Expression Studies, Protein Production, Transgenic Models, Therapeutic Delivery, Cancer Research, Biomedical Research)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Transfection Reagent and Equipment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Method
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Transfection Reagent and Equipment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Method
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Transfection Reagent and Equipment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Method
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Transfection Reagent and Equipment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Method
      • 6.3.3.2.2. By Application

7. Europe Transfection Reagent and Equipment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Method
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Transfection Reagent and Equipment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Method
      • 7.3.1.2.2. By Application
  • 7.3.2. France Transfection Reagent and Equipment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Method
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Transfection Reagent and Equipment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Method
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Transfection Reagent and Equipment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Method
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Transfection Reagent and Equipment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Method
      • 7.3.5.2.2. By Application

8. Asia Pacific Transfection Reagent and Equipment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Method
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Transfection Reagent and Equipment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Method
      • 8.3.1.2.2. By Application
  • 8.3.2. India Transfection Reagent and Equipment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Method
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Transfection Reagent and Equipment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Method
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Transfection Reagent and Equipment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Method
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Transfection Reagent and Equipment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Method
      • 8.3.5.2.2. By Application

9. Middle East & Africa Transfection Reagent and Equipment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Method
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Transfection Reagent and Equipment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Method
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Transfection Reagent and Equipment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Method
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Transfection Reagent and Equipment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Method
      • 9.3.3.2.2. By Application

10. South America Transfection Reagent and Equipment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Method
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Transfection Reagent and Equipment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Method
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Transfection Reagent and Equipment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Method
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Transfection Reagent and Equipment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Method
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Transfection Reagent and Equipment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Promega Corporation
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. Bio-Rad Laboratories Inc.
• 15.5. Merck KGaA
• 15.6. OriGene Technologies Inc.
• 15.7. MaxCyte, Inc.
• 15.8. POLYPLUS TRANSFECTION S.A.
• 15.9. Horizon Discovery Ltd.
• 15.10. PromoCell GmbH

16. Strategic Recommendations

17. About Us & Disclaimer